Registry on WATCHMAN Outcomes in Real-Life Utilization (EWOLUTION)
Sponsor: Boston Scientific Corporation
A observational or N/A phase clinical study on Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke, this trial is completed. The trial is conducted by Boston Scientific Corporation and has accumulated 11 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed
-
Jun 2019 — Jan 2021 [monthly]
Completed
Status: Unknown Status → Completed
-
Jun 2018 — Jun 2019 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Belfast, United Kingdom , Berlin, Germany , Bielefeld, Germany , Bonn, Germany , Bordeaux, France , Bydgoszcz, Poland , Catania, Italy , Cirié, Italy , Créteil, France and 33 more locations